239 related articles for article (PubMed ID: 27565715)
1. Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.
Wong YY; Rakasz EG; Gasper DJ; Friedrich TC; Trepanier LA
Toxicology; 2016 Aug; 368-369():10-18. PubMed ID: 27565715
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.
Abouraya M; Sacco JC; Kahl BS; Trepanier LA
Br J Clin Pharmacol; 2011 Apr; 71(4):566-74. PubMed ID: 21204907
[TBL] [Abstract][Full Text] [Related]
3. Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.
Bhusari S; Abouraya M; Padilla ML; Pinkerton ME; Drescher NJ; Sacco JC; Trepanier LA
Arch Toxicol; 2010 Aug; 84(8):597-607. PubMed ID: 20221587
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group.
Walmsley SL; Khorasheh S; Singer J; Djurdjev O
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):498-505. PubMed ID: 9859964
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study.
Lavergne SN; Volkman EM; Maki JE; Yoder AR; Trepanier LA
Toxicology; 2005 Mar; 208(1):63-72. PubMed ID: 15664433
[TBL] [Abstract][Full Text] [Related]
6. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
Feola DJ; Garvy BA; Rapp RP; Thornton AC
Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.
Carr A; Penny R; Cooper DA
AIDS; 1993 Jan; 7(1):65-71. PubMed ID: 8442919
[TBL] [Abstract][Full Text] [Related]
8. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction.
Pyle RC; Butterfield JH; Volcheck GW; Podjasek JC; Rank MA; Li JT; Harish A; Poe KL; Park MA
J Allergy Clin Immunol Pract; 2014; 2(1):52-8. PubMed ID: 24565769
[TBL] [Abstract][Full Text] [Related]
9. The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus.
Lehmann DF; Liu A; Newman N; Blair DC
J Clin Pharmacol; 1999 May; 39(5):533-7. PubMed ID: 10234602
[TBL] [Abstract][Full Text] [Related]
10. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals.
Neuman MG; Malkiewicz IM; Phillips EJ; Rachlis AR; Ong D; Yeung E; Shear NH
Ther Drug Monit; 2002 Dec; 24(6):728-36. PubMed ID: 12451289
[TBL] [Abstract][Full Text] [Related]
11. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
Buijs BS; van den Berk GE; Boateng CP; Hoepelman AI; van Maarseveen EM; Arends JE
AIDS; 2015 Apr; 29(7):785-91. PubMed ID: 25985401
[TBL] [Abstract][Full Text] [Related]
12. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
Fisher RG; Nageswaran S; Valentine ME; McKinney RE
AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
[TBL] [Abstract][Full Text] [Related]
13. Trimethoprim-sulfamethoxazole exposure alters ex vivo function of B lymphocytes isolated from human immunodeficiency virus-infected patients receiving Zidovudine.
Venugopalan V; Thornton AC; Steinke DT; Rapp RP; Romanelli F; Feola DJ
Pharmacotherapy; 2009 Apr; 29(4):373-82. PubMed ID: 19323617
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV.
Carr A; Tindall B; Penny R; Cooper DA
Clin Exp Immunol; 1993 Oct; 94(1):21-5. PubMed ID: 8403509
[TBL] [Abstract][Full Text] [Related]
15. Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy.
Vesterbacka J; Barqasho B; Häggblom A; Nowak P
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):830-6. PubMed ID: 26059763
[TBL] [Abstract][Full Text] [Related]
16. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.
Carr A; Gross AS; Hoskins JM; Penny R; Cooper DA
AIDS; 1994 Mar; 8(3):333-7. PubMed ID: 8031511
[TBL] [Abstract][Full Text] [Related]
17. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting.
Nguyen AT; Gentry CA; Furrh RZ
Curr Drug Saf; 2013 Apr; 8(2):114-9. PubMed ID: 23713542
[TBL] [Abstract][Full Text] [Related]
18. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso.
Lavergne SN; Kurian JR; Bajad SU; Maki JE; Yoder AR; Guzinski MV; Graziano FM; Trepanier LA
Toxicology; 2006 May; 222(1-2):25-36. PubMed ID: 16473451
[TBL] [Abstract][Full Text] [Related]
19. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients.
Nguyen MT; Weiss PJ; Wallace MR
AIDS; 1995 Jun; 9(6):573-5. PubMed ID: 7662195
[TBL] [Abstract][Full Text] [Related]
20. [Desensitization to trimethoprim-sulfamethoxazole in patients with HIV infection].
Piketty C; Gilqouin J; Kazatchkine M
Ann Med Interne (Paris); 1996; 147(5):327-30. PubMed ID: 9033734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
